Eli Lilly Ready to Roll Out Weight-Loss Pill in India After Regulatory Clearance
What Happened
Eli Lilly has said it is ready to launch its once-daily oral obesity and type-2 diabetes drug, Foundayo (orforglipron), in India as soon as it receives regulatory approval. David Ricks, Chair and CEO of Eli Lilly, said the company is prepared for an immediate rollout, with a potential launch targeted for 2027. The pill would offer a non-injectable alternative to weight-loss treatments such as Mounjaro.
Key Takeaways
The oral drug could significantly expand access to obesity treatment in India by offering a more convenient alternative to injections. India is also expected to play a major role in manufacturing the medicine for global supply, with Eli Lilly investing heavily in local production partnerships.